

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Brain glioblastoma (GBM)
NAME Chang, Tsui-Chiung
DATE OF BIRTH 24 January 1946
SEX Female
MEDICAL RECORD # 46470422

PHYSICIAN

ORDERING PHYSICIAN Lin, Chun-Fu
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN SITE Brain
SPECIMEN ID S110-23412 B (PF21025)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 13 August 2021
SPECIMEN RECEIVED 01 October 2021

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 4 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

EGFR amplification, EGFRvIII
HGF amplification
CDKN2A/B CDKN2A loss, CDKN2B loss
MTAP loss exons 2-8
TERT promoter -124C>T

2 Disease relevant genes with no reportable alterations: **IDH1, PDGFRA**

2 Therapies with Clinical Benefit
0 Therapies with Resistance

9 Clinical Trials

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 4 Muts/Mb

GENOMIC FINDINGS

EGFR - amplification, EGFRvIII

8 Trials *see p. 9*

HGF - amplification

1 Trial *see p. 11*

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. *see Biomarker Findings section*

No therapies or clinical trials. *see Biomarker Findings section*

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
none	Cetuximab
	Panitumumab
none	none

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2A loss, CDKN2B loss p. 5 **TERT** - promoter -124C>T p. 7
MTAP - loss exons 2-8 p. 6

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

ORDERED TEST # ORD-1203926-01

BIOMARKER FINDINGS

BIOMARKER

Microsatellite status

RESULT

MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁻³, including approved therapies nivolumab and pembrolizumab⁴. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and

experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, $p=0.001$)⁵.

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples⁶⁻⁸. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples⁶, although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs⁹. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM⁶, in GBMs with a previous lower grade astrocytoma⁷, and in giant cell GBM compared to classic GBM⁸.

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor¹⁰. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2¹⁰⁻¹². This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers¹³⁻¹⁵. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{10,12,14-15}.

BIOMARKER

Tumor Mutational Burden

RESULT

4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1¹⁶⁻¹⁸, anti-PD-1 therapies¹⁶⁻¹⁹, and combination nivolumab and ipilimumab²⁰⁻²⁵. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported^{16,26-27}. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE

mutations have benefited from treatment with anti-PD-1²⁸⁻²⁹ or anti-PD-L1³⁰ therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (mut/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)³¹. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB³²⁻³³. Increased TMB has been reported to correlate with higher tumor grade in glioma³⁴ and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency

(bMMRD)²⁸, as well as with shorter OS of patients with diffuse glioma³⁵.

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma³⁶⁻³⁷ and cigarette smoke in lung cancer³⁸⁻³⁹, treatment with temozolomide-based chemotherapy in glioma⁴⁰⁻⁴¹, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes⁴²⁻⁴⁶, and microsatellite instability (MSI)^{42,45-46}. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents^{16,26-30}.

ORDERED TEST # ORD-1203926-01

GENOMIC FINDINGS

GENE

EGFR

ALTERATION

amplification, EGFRvIII

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

In multiple glioblastoma (GBM) studies, the presence of EGFRvIII has not predicted clinical benefit from first-generation EGFR TKIs such as erlotinib⁴⁷⁻⁵² or gefitinib^{50,53}. However, case reports have described patients with EGFRvIII-positive GBM responding to erlotinib⁵⁴⁻⁵⁷. In a retrospective study of patients with GBM treated with erlotinib or gefitinib, co-expression of EGFRvIII with PTEN protein was the strongest predictor of response ($P < 0.001$)⁵⁸, suggesting that activity in this setting is dependent on PTEN status⁵⁹⁻⁶⁰. However, a prospective Phase 2 trial testing erlotinib monotherapy for patients with EGFRvIII and PTEN-positive recurrent glioblastoma reported minimal efficacy and was terminated⁵². The second-generation EGFR TKIs afatinib and dacomitinib have shown minimal efficacy for patients with EGFRvIII glioblastoma (GBM)⁶¹⁻⁶⁴. A Phase 1/2 study of afatinib, temozolomide, or the combination for patients with GBM reported clinical benefit, including for patients with EGFRvIII; however, temozolomide alone and in combination exhibited better responses than afatinib monotherapy⁶¹⁻⁶². A Phase 2 trial of dacomitinib for patients with EGFR-amplified GBM reported a DCR of 26% (5/19) among patients with EGFR amplification and EGFRvIII; however, the trial failed to meet its primary endpoint of 6-month PFS⁶³. A retrospective biomarker analysis of another Phase 2 study of dacomitinib for patients with GBM found no association between EGFRvIII and clinical benefit⁶⁴. A patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFRvIII, experienced progression of the EGFRvIII-positive tumor during treatment with osimertinib⁶⁵. Novel approaches that specifically target EGFRvIII in glioblastoma (GBM), such as the vaccine rindopepimut, are under investigation in both clinical and preclinical studies. A Phase 2 trial reported significant

improvement in OS for patients with EGFRvIII-positive GBM with rindopepimut in combination with bevacizumab compared to bevacizumab alone ($HR = 0.53$, $p = 0.01$)⁶⁶. However, a Phase 3 study of rindopepimut combined with temozolomide compared to temozolomide alone in newly diagnosed EGFRvIII-positive GBM patients was terminated after the interim analysis, due to a lack of clinical benefit as measured by OS (20 vs. 20 months)⁶⁷. Clinical studies of the second-generation EGFR TKIs afatinib and dacomitinib for patients with EGFR-amplified gliomas have shown limited efficacy^{61,63-64,68-69}; however, a small subset of patients has experienced clinical benefit^{63-64,68}. Multiple studies have failed to find a positive association between increased EGFR expression and clinical benefit from erlotinib or gefitinib for patients with glioblastoma^{58,70-72}. There are conflicting data on the efficacy of anti-EGFR antibodies for the treatment of EGFR-amplified tumors. A meta-analysis of colorectal cancer patients treated with second-line or higher cetuximab or panitumumab observed an association between EGFR copy number gain and increased OS and PFS⁷³. However, studies in head and neck squamous cell carcinoma and gastric cancer found either no association or a negative association between EGFR copy number gain and survival after treatment with first-line cetuximab or panitumumab in combination with chemotherapy⁷⁴⁻⁷⁵. The Phase 3 INTELLANCE trial of depatuxizumab mafodotin (ABT-414), an EGFR-targeted antibody-drug conjugate with a toxic payload, in patients with EGFR-amplified glioblastoma (GBM) was stopped for futility. Interim analysis demonstrated improved median PFS (mPFS) of ABT-414 monotherapy compared with placebo ($HR = 0.84$); however, no OS benefit was observed ($HR = 1.01$). Improved mPFS was also observed in patients harboring EGFRvIII ($HR = 0.73$) but without an OS improvement ($HR = 0.95$)⁷⁶. The Phase 2 INTELLANCE trial demonstrated clinical benefit for EGFR-amplified GBM for the combination of ABT-414, temozolomide, and radiotherapy ($HR = 0.66$, $p = 0.017$), but there was no evidence of efficacy for ABT-414 monotherapy ($HR = 1.04$, $p = 0.83$)⁷⁷.

FREQUENCY & PROGNOSIS

Across several genomic studies of CNS tumors, EGFR alterations have been reported in 13.2% of

anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas⁷⁸⁻⁸¹. Across several genomic studies of CNS tumors, EGFR amplification has been reported in 16.9% of anaplastic astrocytomas, and 39.7% of glioblastoma multiformes (GBMs)⁷⁸⁻⁸¹. In the glioblastoma (GBM) TCGA dataset, putative high-level amplification of EGFR has been found in 48% of cases and mutation has been found in 21% of cases⁷⁹. Missense mutations in the EGFR extracellular domain have been found in 10-15% of GBMs and approximately half have a low-level amplification of the mutated allele⁸²⁻⁸³. One study detected EGFR alterations in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event⁸⁴. The EGFRvIII mutation has been variously reported in 6-46% of GBM samples^{58,85-92}. No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM⁹³⁻⁹⁴; however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM⁹⁵. The link between EGFRvIII status and prognosis is unclear, although some studies suggest that it may be linked to improved survival and response to chemotherapy⁹⁶.

FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide⁹⁷. Amplification of EGFR has been associated with increased expression of EGFR mRNA and protein in several cancer types⁹⁸⁻¹⁰⁰. A mutation of the EGFR gene, referred to as EGFRvIII, results from a gene rearrangement that deletes exons 2-7. This alteration causes an in-frame deletion of 801 base pairs encoding part of the extracellular ligand-binding domain⁸⁵. This deletion has shown to result in ligand-independent (constitutive) phosphorylation and activation of EGFR, as well as consequent tumorigenesis^{85,101}.

ORDERED TEST # ORD-1203926-01

GENOMIC FINDINGS

GENE

HGF

ALTERATION

amplification

bevacizumab¹⁰⁷, tumor HGF gene expression did not predict significant benefit from onartuzumab added to the EGFR-inhibitor erlotinib for patients with non-small cell lung cancer¹⁰⁸. Anti-HGF antibodies, such as ficlatuzumab, are also under clinical investigation¹⁰⁹⁻¹¹⁰.

glioma and increased microvessels, and tumor-derived HGF expression has been shown to correlate with reduced survival time¹¹⁷. Elevated expression of HGF and MET mRNA have been reported in GBM¹¹⁸⁻¹¹⁹, and HGF expression in GBM models has been shown to be associated with responsiveness to MET inhibition¹⁰².

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of several preclinical studies in different cancer types, high HGF gene expression may associate with sensitivity to MET-targeted therapies, such as the approved multikinase inhibitors crizotinib and cabozantinib¹⁰²⁻¹⁰⁶. However, this hypothesis has not been extensively tested in clinical studies. Whereas patients with glioblastoma and high tumor HGF gene expression experienced longer survival and a higher objective response rate (5/14 vs. 0/16) on the MET-targeting antibody onartuzumab combined with the anti-VEGF antibody bevacizumab than with placebo plus

— Potential Resistance —

Preclinical studies have shown that increased HGF protein levels can induce resistance of EGFR-mutant lung tumors to EGFR inhibitors and of BRAF-mutant melanoma cells to RAF inhibitors; this resistance could be overcome by combination therapy with MET inhibitors¹¹¹⁻¹¹⁶.

FREQUENCY & PROGNOSIS

HGF amplification has been reported in less than 1% of samples in lower-grade gliomas and in up to 1.6% of glioblastoma cases; mutation has been observed in <0.5% of gliomas (cBioPortal, COSMIC, Nov 2020)⁷⁹. HGF expression within tumor glioma cells is associated with high-grade

FINDING SUMMARY

HGF encodes hepatocyte growth factor, also known as scatter factor, an activating ligand of the receptor tyrosine kinase MET. Certain splice isoforms of HGF may also act as MET antagonists¹²⁰⁻¹²¹. HGF plays an important role in normal development, acting as a growth factor in a number of different tissues¹²⁰⁻¹²¹. HGF and its receptor, MET, have been implicated in growth, invasion, and metastasis of many solid tumors¹²¹. HGF has been reported to be amplified in cancer¹²², and may be biologically relevant in this context¹²³⁻¹²⁴.

ORDERED TEST # ORD-1203926-01

GENOMIC FINDINGS

GENE

CDKN2A/B

ALTERATION

CDKN2A loss, CDKN2B loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib¹²⁵⁻¹²⁸. Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment¹²⁹⁻¹³⁰, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents¹³¹⁻¹³⁷; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors¹³⁸⁻¹³⁹, the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib^{132,134-135,140-142}.

FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of

CDKN2A and CDKN2B has been reported in 35% of patients with gliomas⁸⁰ and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)⁷⁹ than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)^{122,143}. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)^{91,144-145}. A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone¹⁴⁶. One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed⁸⁴. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples¹⁴⁷. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression^{144,148}. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas¹⁴⁹⁻¹⁵⁰.

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b¹⁵¹⁻¹⁵². Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby

maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control¹⁵³⁻¹⁵⁴. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition¹⁵⁵⁻¹⁵⁶. One or more alterations observed here are predicted to result in p16INK4a loss of function¹⁵⁷⁻¹⁷⁸. One or more alterations seen here are predicted to result in p14ARF loss of function^{161,178-181}. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b¹⁸².

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer¹⁸³. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma¹⁸⁴⁻¹⁸⁵. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases¹⁸⁶⁻¹⁸⁸. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors¹⁸⁹⁻¹⁹¹. In the appropriate clinical context, germline testing of CDKN2A is recommended.

ORDERED TEST # ORD-1203926-01

GENOMIC FINDINGS

GENE

MTAP

ALTERATION

loss exons 2-8

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical and limited clinical evidence indicate that MTAP inactivation produces specific metabolic vulnerabilities. MTAP inactivation may confer sensitivity to MAT2A inhibitors¹⁹². A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss¹⁹³. Although preclinical data have suggested that MTAP loss sensitizes cells to PRMT5 inhibition^{192,194-195}, MTAP loss may not be a biomarker of response to previously developed small-molecule SAM-uncompetitive PRMT5 inhibitors¹⁹⁶; dual PRMT1 and PRMT5 inhibition may be more effective¹⁹⁷⁻¹⁹⁹. In preclinical cancer models, MTAP inactivation showed increased

sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA, which is converted to adenine in normal cells, thereby providing competition to purine poisons lacking in MTAP-deficient cells²⁰⁰⁻²¹⁰. A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and stable disease in 23.6% (13/55) of patients²¹¹.

FREQUENCY & PROGNOSIS

MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers²¹²⁻²¹³; such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma²¹⁴, gastrointestinal stromal tumors²¹⁵, mantle cell lymphoma (MCL)²¹⁶, melanoma²¹⁷⁻²¹⁸, gastric cancer²¹⁹, myxofibrosarcoma²²⁰, nasopharyngeal carcinoma²²¹, ovarian carcinoma²¹² and non-small cell lung cancer²²². MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia²²³ or in astrocytoma²²⁴. However, MTAP has also

been reported to be overexpressed in colorectal cancer (CRC) samples²²⁵, and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM²²⁶. Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma²²⁷⁻²²⁸, esophageal cancer²²⁹⁻²³⁰, osteosarcoma²³¹, and CRC²³².

FINDING SUMMARY

MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity²³³⁻²³⁴. Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment^{214,235-236}, thereby reducing intracellular arginine methylation^{192,194,237} and altering cell signaling^{236,238}. MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized.

ORDERED TEST # ORD-1203926-01

GENOMIC FINDINGS

GENE

TERT

ALTERATION

promoter -124C>T

TRANSCRIPT ID

NM_198253

CODING SEQUENCE EFFECT

-124C>T

VARIANT ALLELE FREQUENCY (% VAF)

25.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches are under development, including immunotherapies utilizing TERT as a tumor-associated antigen, antisense oligonucleotide- or peptide-based therapies, and TERT promoter-directed cytotoxic molecules.

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas²³⁹⁻²⁴⁰, most frequently in

glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas²³⁹⁻²⁴³. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)^{239,241}. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed⁸⁴. The significance of the TERT promoter mutation as an independent prognostic indicator in patients with glioma is not clear. While TERT promoter mutations significantly associate with poor prognosis in patients with GBM, this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM^{239,241,244-245}. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS, whereas in IDH-mutated, 1p/19q co-deleted oligodendroglioma, TERT mutations are associated with improved OS (NCCN CNS Cancers Guidelines, v5.2020). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM²⁴⁵.

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length²⁴⁶. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells²⁴⁷⁻²⁴⁹. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)²⁵⁰⁻²⁵², as well as tandem mutations at positions -124/-125 bp and -138/-139 bp²⁵⁰.

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v5.2020). Co-occurring TERT mutation, IDH mutation, and 1p/19q co-deletion is indicative of oligodendroglioma, whereas IDH mutation in the absence of TERT mutation is suggestive of astrocytoma (NCCN CNS Cancers Guidelines, v5.2020).

ORDERED TEST # ORD-1203926-01

THERAPIES WITH CLINICAL BENEFIT

IN OTHER TUMOR TYPE

Cetuximab

Assay findings association

EGFR

amplification, EGFRvIII

AREAS OF THERAPEUTIC USE

Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies⁷³.

SUPPORTING DATA

A Phase 3 trial of combined cetuximab and platinum/5-FU in patients with HNSCC demonstrated improved response compared to platinum/5-FU alone, but EGFR amplification was not shown to predict response to this treatment⁷⁴. A Phase 3 study of patients with pancreatic adenocarcinoma did not report any improved outcome in patients treated with a combination of cetuximab plus

gemcitabine vs gemcitabine alone²⁵³. In a Phase 1/2 trial of 36 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cetuximab in combination with doxorubicin, stable disease was reported in approximately 63% of patients²⁵⁴. A Phase 1 study of the combination therapy of cetuximab, erlotinib, and bevacizumab reported stable disease in 21% (7/34) of patients with non-small cell lung cancer (NSCLC)²⁵⁵. A clinical trial of cetuximab with bevacizumab (an anti-VEGF monoclonal antibody) in patients with glioblastoma (GBM) did not show improved efficacy compared with bevacizumab alone²⁵⁶. In preclinical trials, cetuximab, matuzumab, and panitumumab were reported to be ineffective at blocking EGFR dimerization and activation in GBM cells expressing EGFR extracellular domain mutations²⁵⁷. However, another study demonstrated that in patients with GBM harboring EGFR amplification but lacking expression of the EGFRvIII variant, treatment with cetuximab resulted in significantly better progression-free survival (PFS) and numerical (although not statistically significant) improvement in overall survival (OS)⁹².

Panitumumab

Assay findings association

EGFR

amplification, EGFRvIII

AREAS OF THERAPEUTIC USE

Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies⁷³.

SUPPORTING DATA

A Phase 1 trial of EnGeneIC delivery vehicle (EDV) targeting EGFR with panitumumab in combination with

doxorubicin for 14 patients with glioblastoma (GBM) reported no responses and 28% (4/14) SDs²⁵⁸. Panitumumab has shown efficacy as monotherapy or in combination with chemotherapy for patients with KRAS-wildtype colorectal cancer²⁵⁹⁻²⁶¹ and has been investigated in a variety of other tumor types. For patients with head and neck squamous cell carcinoma (HNSCC), data are conflicting; some trials of panitumumab in various lines and with different chemotherapy combinations have shown modest benefit²⁶²⁻²⁶⁴ and others have reported no benefit²⁶⁵⁻²⁶⁷. A Phase 3 study of chemotherapy with or without panitumumab for patients with advanced gastroesophageal cancer was terminated for futility²⁶⁸. Trials in a variety of tumor types have failed to show significant benefit for patients, including non-small cell lung cancer (NSCLC)²⁶⁹⁻²⁷⁰; biliary tract cancers, including cholangiocarcinoma²⁷¹⁻²⁷²; and renal cell carcinoma (RCC)²⁷³.

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

ORDERED TEST # ORD-1203926-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and

should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require

medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see [clinicaltrials.gov](https://www.foundationmedicine.com/genomic-testing#support-services). Or visit <https://www.foundationmedicine.com/genomic-testing#support-services>.

GENE
EGFR
ALTERATION
 amplification, EGFRvIII

RATIONALE
 EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome

resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT03618667
PHASE 2

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

TARGETS
 EGFR

LOCATIONS: Seoul (Korea, Republic of)

NCT04172597
PHASE 2

A Study of Pozitotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies

TARGETS
 EGFR, ERBB2, ERBB4

LOCATIONS: California

NCT02800486
PHASE 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbix) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

TARGETS
 EGFR

LOCATIONS: New York

NCT02861898
PHASE 1/2

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

TARGETS
 EGFR

LOCATIONS: New York

NCT03783403
PHASE 1

 A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP α , in Subjects With Advanced Solid and Hematologic Cancers

TARGETS
 CD20, EGFR, SIRP-alpha

LOCATIONS: Heidelberg (Australia), Melbourne (Australia), Edmonton (Canada), California, Colorado, Arizona, Toronto (Canada), Oklahoma, Texas, Pennsylvania

ORDERED TEST # ORD-1203926-01

CLINICAL TRIALS

NCT02451553
PHASE 1

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

TARGETS
 EGFR, ERBB2, ERBB4

LOCATIONS: Washington

NCT03829436
PHASE 1

TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers

TARGETS
 PD-1, PPARalpha

LOCATIONS: California, Michigan, Oklahoma, Pennsylvania, New York, Tennessee, Maryland, North Carolina, Florida

NCT02303678
PHASE 1

D2C7 for Adult Patients With Recurrent Malignant Glioma

TARGETS
 EGFRvIII

LOCATIONS: North Carolina

ORDERED TEST # ORD-1203926-01

CLINICAL TRIALS

GENE
HGF
RATIONALE
 HGF amplification or activating mutations may predict sensitivity to therapeutic agents targeting

its receptor, MET, or to agents directly targeting HGF.

ALTERATION
 amplification

NCT03175224
PHASE 1/2

CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation

TARGETS
MET
LOCATIONS: Taipei City (Taiwan), Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Tainan (Taiwan), Singapore (Singapore), Nedlands (Australia), Saransk (Russian Federation), North Adelaide (Australia), Bedford Park (Australia)

ORDERED TEST # ORD-1203926-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

BARD1
A613G

BRIP1
N775S

IKBKE
V480M

PIK3R1
H407Q

TEK
loss

ORDERED TEST # ORD-1203926-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTB	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXO2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNAI1	GNAI3	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDMSA	KDMS5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKB1A	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOC3
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
 Microsatellite (MS) status
 Tumor Mutational Burden (TMB)

ORDERED TEST # ORD-1203926-01

APPENDIX

About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.


ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. The MSI-H/MSS designation by FMI F1CDx test is based on genome wide analysis of 95 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines. The threshold for MSI-H/MSS was determined by analytical concordance to comparator assays (IHC and PCR) using uterine, cecum and colorectal cancer FFPE tissue. The clinical validity of the qualitative MSI designation has not been established. For Microsatellite Instability (MSI) results, confirmatory testing using a validated orthogonal method should be considered.
2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics

© 2021 Foundation Medicine, Inc. All rights reserved.

ORDERED TEST # ORD-1203926-01

APPENDIX

About FoundationOne®CDx

of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive,

and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of *HER2* overexpression as 20% in breast cancer. Based on the F1CDx *HER2* CDx concordance study, approximately 10% of *HER2* amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*,

RAD51C, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating

ORDERED TEST # ORD-1203926-01

APPENDIX

About FoundationOne®CDx

physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/m	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.0.0

The median exon coverage for this sample is 565x

© 2021 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Erik Williams, M.D. | 14 October 2021
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1203926-01

APPENDIX
References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) PMID: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) PMID: 26140250
3. Lal N, et al. Oncoimmunology (2015) PMID: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) PMID: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) PMID: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) PMID: 17498554
9. Szybka M, et al. Clin. Neuropathol. () PMID: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) PMID: 26337942
11. You JF, et al. Br. J. Cancer (2010) PMID: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) PMID: 24623249
13. Boland CR, et al. Cancer Res. (1998) PMID: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) PMID: 15528785
15. Boland CR, et al. Gastroenterology (2010) PMID: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) PMID: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) PMID: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) PMID: 31405947
19. Cristescu R, et al. Science (2018) PMID: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) PMID: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) PMID: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) PMID: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) PMID: 29731394
24. Rozeman EA, et al. Nat Med (2021) PMID: 33558721
25. Sharma P, et al. Cancer Cell (2020) PMID: 32916128
26. Zhao J, et al. Nat. Med. (2019) PMID: 30742119
27. Touat M, et al. Nature (2020) PMID: 32322066
28. Bouffett E, et al. J. Clin. Oncol. (2016) PMID: 27001570
29. Johanns TM, et al. Cancer Discov (2016) PMID: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) PMID: 30073642
31. Chalmers ZR, et al. Genome Med (2017) PMID: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) PMID: 32386112
33. Johnson A, et al. Oncologist (2017) PMID: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) PMID: 26699864
35. Wang L, et al. BMC Cancer (2020) PMID: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
38. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
39. Rizvi NA, et al. Science (2015) PMID: 25765070
40. Johnson BE, et al. Science (2014) PMID: 24336570
41. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
43. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
45. Nature (2012) PMID: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
47. van den Bent MJ, et al. J Clin Oncol (2009) PMID: 19204207
48. Haas-Kogan DA, et al. J Natl Cancer Inst (2005) PMID: 15956649
49. Brown PD, et al. J Clin Oncol (2008) PMID: 18955445
50. Preusser M, et al. J Neurooncol (2008) PMID: 18458820
51. Wen PY, et al. Neuro-oncology (2014) PMID: 24470557
52. Gallego O, et al. J Neurooncol (2014) PMID: 24352766
53. Uhm JH, et al. Int J Radiat Oncol Biol Phys (2011) PMID: 20510539
54. Doyle SP, et al. Oxf Med Case Reports (2018) PMID: 30410775
55. D'Alessandris QG, et al. Acta Neurochir (Wien) (2013) PMID: 23132371
56. Custodio A, et al. Clin Transl Oncol (2010) PMID: 20462843
57. D'Alessandris QG, et al. Acta Neurochir (Wien) (2018) PMID: 30306271
58. Mellinghoff IK, et al. N. Engl. J. Med. (2005) PMID: 16282176
59. Mellinghoff IK, et al. Clin Cancer Res (2007) PMID: 17255257
60. Arif SH, et al. Asian J Neurosurg () PMID: 29492119
61. Reardon DA, et al. Neuro-oncology (2015) PMID: 25140039
62. Alshami J, et al. Oncotarget (2015) PMID: 26423602
63. Sepúlveda-Sánchez JM, et al. Neuro-oncology (2017) PMID: 28575464
64. Chi AS, et al. JCO Precis Oncol (2020) PMID: 32923886
65. Makhlin I, et al. CNS Oncol (2019) PMID: 31769726
66. Reardon DA, et al. Clin Cancer Res (2020) PMID: 32034072
67. Weller M, et al. Lancet Oncol (2017) PMID: 28844499
68. Tanaka S, et al. Sci Rep (2019) PMID: 30644426
69. Blumenthal DT, et al. J. Neurooncol. (2016) PMID: 27531351
70. Franceschi E, et al. Br. J. Cancer (2007) PMID: 17353924
71. Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) PMID: 23182702
72. Hegi ME, et al. Mol. Cancer Ther. (2011) PMID: 21471286
73. Jiang Z, et al. PLoS ONE (2013) PMID: 23441167
74. Licitra L, et al. Ann. Oncol. (2011) PMID: 21048039
75. Smyth EC, et al. Gut (2021) PMID: 33199443
76. Lassman et al., 2019; Neuro-Oncology Abstract ACTR-21
77. Van Den Bent M, et al. Neuro Oncol (2020) PMID: 31747009
78. Jonsson P, et al. Clin. Cancer Res. (2019) PMID: 31263031
79. Brennan CW, et al. Cell (2013) PMID: 24120142
80. Ceccarelli M, et al. Cell (2016) PMID: 26824661
81. Thomas AA, et al. Neuro-oncology (2017) PMID: 28472509
82. Lee JC, et al. PLoS Med. (2006) PMID: 17177598
83. Vivanco I, et al. Cancer Discov (2012) PMID: 22588883
84. Yan et al. 2020; DOI:10.1200/PO.19.00385
85. Nishikawa R, et al. Proc. Natl. Acad. Sci. U.S.A. (1994) PMID: 8052651
86. Shinjima N, et al. Cancer Res. (2003) PMID: 14583498
87. Nishikawa R, et al. Brain Tumor Pathol (2004) PMID: 15700833
88. Viana-Pereira M, et al. Anticancer Res. () PMID: 18507036
89. Yoshimoto K, et al. Clin. Cancer Res. (2008) PMID: 18223223
90. Larysz D, et al. Folia Neuropathol (2011) PMID: 21455841
91. Verhaak RG, et al. Cancer Cell (2010) PMID: 20129251
92. Lv S, et al. Int. J. Oncol. (2012) PMID: 22752145
93. Srividya MR, et al. J. Clin. Pathol. (2010) PMID: 20702468
94. Das P, et al. J Clin Neurosci (2011) PMID: 20888234
95. Smith JS, et al. J. Natl. Cancer Inst. (2001) PMID: 11504770
96. Montano N, et al. Neoplasia (2011) PMID: 22241957
97. Ciardiello F, et al. N. Engl. J. Med. (2008) PMID: 18337605
98. Liang Z, et al. BMC Cancer (2010) PMID: 20637128
99. Bhargava R, et al. Mod. Pathol. (2005) PMID: 15920544
100. Yang YL, et al. Chin. Med. J. (2012) PMID: 22490401
101. Nedergaard MK, et al. BioDrugs (2012) PMID: 22385404
102. Zhang Y, et al. Clin. Cancer Res. (2013) PMID: 23386689
103. Xie Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) PMID: 22203985
104. Kentsis A, et al. Nat. Med. (2012) PMID: 22683780
105. Xie Q, et al. Genes Cancer (2013) PMID: 24167653
106. Wanjala J, et al. Mol. Cancer Ther. (2015) PMID: 25381262
107. Cloughesy et al., 2015; ASCO Abstract 2015
108. Koepfen H, et al. Clin. Cancer Res. (2014) PMID: 24687921
109. Patnaik A, et al. Br. J. Cancer (2014) PMID: 24901237
110. Iveson T, et al. Lancet Oncol. (2014) PMID: 24965569
111. Yano S, et al. Cancer Res. (2008) PMID: 19010923
112. Turke AB, et al. Cancer Cell (2010) PMID: 20129249
113. Nakade J, et al. J Thorac Oncol (2014) PMID: 24828661
114. Nanjo S, et al. PLoS ONE (2013) PMID: 24386407
115. Chen X, et al. Anticancer Drugs (2013) PMID: 23962905
116. Straussman R, et al. Nature (2012) PMID: 22763439
117. Guo YF, et al. World J Surg Oncol (2012) PMID: 22741575
118. Garnett J, et al. Neoplasia (2013) PMID: 23359207
119. Kunkel P, et al. Neuro-oncology (2001) PMID: 11296484
120. Stamos J, et al. EMBO J. (2004) PMID: 15167892
121. Tolbert WD, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) PMID: 20624990
122. Gao J, et al. Sci Signal (2013) PMID: 23550210
123. Zack TI, et al. Nat. Genet. (2013) PMID: 24071852
124. Beroukhim R, et al. Nature (2010) PMID: 20164920
125. Konecny GE, et al. Clin. Cancer Res. (2011) PMID: 21278246
126. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) PMID: 21871868
127. Cen L, et al. Neuro-oncology (2012) PMID: 22711607
128. Logan JE, et al. Anticancer Res. (2013) PMID: 23898052
129. Elvin JA, et al. Oncologist (2017) PMID: 28283584
130. Gao J, et al. Curr Oncol (2015) PMID: 26715889
131. Gopalan et al., 2014; ASCO Abstract 8077
132. Peguero et al., 2016; ASCO Abstract 2528
133. Konecny et al., 2016; ASCO Abstract 5557
134. DeMichele A, et al. Clin. Cancer Res. (2015) PMID: 25501126
135. Finn RS, et al. Lancet Oncol. (2015) PMID: 25524798
136. Infante JR, et al. Clin. Cancer Res. (2016) PMID: 27542767
137. Johnson DB, et al. Oncologist (2014) PMID: 24797823
138. Van Maerken T, et al. Mol. Cancer Ther. (2011) PMID: 21460101
139. Gamble LD, et al. Oncogene (2012) PMID: 21725357
140. Shapiro et al., 2013; ASCO Abstract 2500
141. Flaherty KT, et al. Clin. Cancer Res. (2012) PMID: 22090362
142. Dickson MA, et al. J. Clin. Oncol. (2013) PMID: 23569312
143. Cerami E, et al. Cancer Discov (2012) PMID: 22588877
144. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) PMID: 23412337
145. Weber RG, et al. Oncogene (2007) PMID: 16909113
146. Nakamura M, et al. Brain Pathol. (2001) PMID: 11303791
147. Chakravarti A, et al. Clin. Cancer Res. (2001) PMID: 11504770

© 2021 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Erik Williams, M.D. | 14 October 2021
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1203926-01

APPENDIX
References

- 11489817
148. Feng J, et al. Cancer (2012) PMID: 21713760
149. Raabe EH, et al. Clin. Cancer Res. (2011) PMID: 21636552
150. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) PMID: 21843312
151. Quelle DE, et al. Cell (1995) PMID: 8521522
152. Mutat. Res. (2005) PMID: 15878778
153. Gazzeri S, et al. Oncogene (1998) PMID: 9484839
154. Oncogene (1999) PMID: 10498883
155. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) PMID: 16869746
156. Ozenne P, et al. Int. J. Cancer (2010) PMID: 20549699
157. Ruas M, et al. Oncogene (1999) PMID: 10498896
158. Jones R, et al. Cancer Res. (2007) PMID: 17909018
159. Haferkamp S, et al. Aging Cell (2008) PMID: 18843795
160. Huot TJ, et al. Mol. Cell. Biol. (2002) PMID: 12417717
161. Rizos H, et al. J. Biol. Chem. (2001) PMID: 11518711
162. Gombart AF, et al. Leukemia (1997) PMID: 9324288
163. Yang R, et al. Cancer Res. (1995) PMID: 7780957
164. Parry D, et al. Mol. Cell. Biol. (1996) PMID: 8668202
165. Greenblatt MS, et al. Oncogene (2003) PMID: 12606942
166. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) PMID: 10491434
167. Poi MJ, et al. Mol. Carcinog. (2001) PMID: 11255261
168. Byeon IJ, et al. Mol. Cell (1998) PMID: 9660926
169. Kannengiesser C, et al. Hum. Mutat. (2009) PMID: 19260062
170. Lal G, et al. Genes Chromosomes Cancer (2000) PMID: 10719365
171. Koh J, et al. Nature (1995) PMID: 7777061
172. McKenzie HA, et al. Hum. Mutat. (2010) PMID: 20340136
173. Miller PJ, et al. Hum. Mutat. (2011) PMID: 21462282
174. Kutscher CL, et al. Physiol. Behav. (1977) PMID: 905385
175. Scaini MC, et al. Hum. Mutat. (2014) PMID: 24659262
176. Jenkins NC, et al. J. Invest. Dermatol. (2013) PMID: 23190892
177. Walker GJ, et al. Int. J. Cancer (1999) PMID: 10389768
178. Rutter JL, et al. Oncogene (2003) PMID: 12853981
179. Itahana K, et al. Cancer Cell (2008) PMID: 18538737
180. Zhang Y, et al. Mol. Cell (1999) PMID: 10360174
181. Zhang Y, et al. Cell (1998) PMID: 9529249
182. Jafri M, et al. Cancer Discov (2015) PMID: 25873077
183. Whelan AJ, et al. N Engl J Med (1995) PMID: 7666917
184. Adv Exp Med Biol (2010) PMID: 20687502
185. Hogg D, et al. J Cutan Med Surg (1998) PMID: 9479083
186. De Unamuno B, et al. Melanoma Res (2018) PMID: 29543703
187. Soura E, et al. J Am Acad Dermatol (2016) PMID: 26892650
188. Huerta C, et al. Acta Derm Venereol (2018) PMID: 29405243
189. Kaufman DK, et al. Neurology (1993) PMID: 8414022
190. Bahuau M, et al. Cancer Res (1998) PMID: 9622062
191. Chan AK, et al. Clin Neuropathol () PMID: 28699883
192. Marjon K, et al. Cell Rep (2016) PMID: 27068473
193. Heist et al., 2019; AACR-NCI-EORTC Abstract B116
194. Mavrikis KJ, et al. Science (2016) PMID: 26912361
195. Endoscopy (1989) PMID: 2691236
196. Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) PMID: 31350521
197. Fedoriv A, et al. Cancer Cell (2019) PMID: 31257072
198. Srour N, et al. Cancer Cell (2019) PMID: 31287990
199. Gao G, et al. Nucleic Acids Res. (2019) PMID: 30916320
200. Hansen LJ, et al. Cancer Res. (2019) PMID: 31040154
201. Tang B, et al. Cancer Res. (2018) PMID: 29844120
202. Munshi PN, et al. Oncologist (2014) PMID: 24928612
203. de Oliveira SF, et al. PLoS ONE (2016) PMID: 26751376
204. Lubin M, et al. PLoS ONE (2009) PMID: 19478948
205. Tang B, et al. Cancer Biol. Ther. (2012) PMID: 22825330
206. Collins CC, et al. Mol. Cancer Ther. (2012) PMID: 22252602
207. Bertino JR, et al. Cancer Biol. Ther. (2011) PMID: 21301207
208. Coulthard SA, et al. Mol. Cancer Ther. (2011) PMID: 21282358
209. Miyazaki S, et al. Int. J. Oncol. (2007) PMID: 17912432
210. Efferth T, et al. Blood Cells Mol. Dis. () PMID: 11987241
211. Kindler HL, et al. Invest New Drugs (2009) PMID: 18618081
212. Wei R, et al. Sci Rep (2016) PMID: 27929028
213. Zhao M, et al. BMC Genomics (2016) PMID: 27556634
214. Kirovski G, et al. Am. J. Pathol. (2011) PMID: 21356366
215. Huang HY, et al. Clin. Cancer Res. (2009) PMID: 19887491
216. Marcé S, et al. Clin. Cancer Res. (2006) PMID: 16778103
217. Meyer S, et al. Exp. Dermatol. (2010) PMID: 20500769
218. Wild PJ, et al. Arch Dermatol (2006) PMID: 16618867
219. Kim J, et al. Genes Chromosomes Cancer (2011) PMID: 21412930
220. Li CF, et al. Oncotarget (2014) PMID: 25426549
221. He HL, et al. Medicine (Baltimore) (2015) PMID: 26656376
222. Su CY, et al. Eur J Surg Oncol (2014) PMID: 24969958
223. Mirebeau D, et al. Haematologica (2006) PMID: 16818274
224. Becker AP, et al. Pathobiology (2015) PMID: 26088413
225. Snezhkina AV, et al. Oxid Med Cell Longev (2016) PMID: 27433286
226. Bistulfi G, et al. Oncotarget (2016) PMID: 26910893
227. Antonopoulou K, et al. J. Invest. Dermatol. (2015) PMID: 25407435
228. Maccioni L, et al. BMC Cancer (2013) PMID: 23816148
229. Hyland PL, et al. Int J Epidemiol (2016) PMID: 26635288
230. Lin X, et al. Cancer Sci. (2017) PMID: 27960044
231. Zhi L, et al. J Cancer (2016) PMID: 27994653
232. Gu F, et al. Br. J. Cancer (2013) PMID: 23361049
233. Limm K, et al. PLoS ONE (2016) PMID: 27479139
234. Tang B, et al. G3 (Bethesda) (2014) PMID: 25387827
235. Limm K, et al. Eur. J. Cancer (2013) PMID: 23265702
236. Stevens AP, et al. J. Cell. Biochem. (2009) PMID: 19097084
237. Kryukov GV, et al. Science (2016) PMID: 26912360
238. Limm K, et al. Eur. J. Cancer (2014) PMID: 25087184
239. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) PMID: 23530248
240. Killela PJ, et al. Oncotarget (2014) PMID: 24722048
241. Nonoguchi N, et al. Acta Neuropathol. (2013) PMID: 23955565
242. Liu X, et al. Cell Cycle (2013) PMID: 23603989
243. Koelsche C, et al. Acta Neuropathol. (2013) PMID: 24154961
244. Reitman ZJ, et al. Acta Neuropathol. (2013) PMID: 24217890
245. Arita H, et al. Acta Neuropathol. (2013) PMID: 23764841
246. Shay JW, et al. Semin. Cancer Biol. (2011) PMID: 22015685
247. Shay JW, et al. Eur. J. Cancer (1997) PMID: 9282118
248. Kim NW, et al. Science (1994) PMID: 7605428
249. Hanahan D, et al. Cell (2000) PMID: 10647931
250. Horn S, et al. Science (2013) PMID: 23348503
251. Huang FW, et al. Science (2013) PMID: 23348506
252. Vinagre J, et al. Nat Commun (2013) PMID: 23887589
253. Philip PA, et al. J. Clin. Oncol. (2010) PMID: 20606093
254. Slovin SF, et al. Clin Genitourin Cancer (2009) PMID: 19815486
255. Falchook GS, et al. Oncotarget (2013) PMID: 23435217
256. Hasselbalch B, et al. Neuro-oncology (2010) PMID: 20406901
257. Gajadhar AS, et al. Mol. Cancer Res. (2012) PMID: 22232519
258. Whittle JR, et al. J Clin Neurosci (2015) PMID: 26279503
259. Douillard JY, et al. Ann. Oncol. (2014) PMID: 24718886
260. Price TJ, et al. Lancet Oncol. (2014) PMID: 24739896
261. Van Cutsem E, et al. J. Clin. Oncol. (2007) PMID: 17470858
262. Vermorken JB, et al. Lancet Oncol (2013) PMID: 23746666
263. Wirth LJ, et al. Ann. Oncol. (2010) PMID: 19892746
264. Siano M, et al. Oncologist (2017) PMID: 28592616
265. Mesia R, et al. Lancet Oncol (2015) PMID: 25596660
266. Giralt J, et al. Lancet Oncol (2015) PMID: 25596659
267. Siu LL, et al. JAMA Oncol (2016) PMID: 27930762
268. Waddell T, et al. Lancet Oncol. (2013) PMID: 23594787
269. Crawford J, et al. J Thorac Oncol (2013) PMID: 24389433
270. Schuette W, et al. Clin Lung Cancer (2015) PMID: 26094080
271. Leone F, et al. Cancer (2016) PMID: 26540314
272. Vogel A, et al. Eur J Cancer (2018) PMID: 29413685
273. Rowinsky EK, et al. J. Clin. Oncol. (2004) PMID: 15210739

© 2021 Foundation Medicine, Inc. All rights reserved.

 Electronically signed by Erik Williams, M.D. | 14 October 2021
 Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
 Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
 Foundation Medicine, Inc. | 1.888.988.3639

 Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
 Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531